Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Among 1330 patients undergoing highly active antiretroviral therapy (HAART), 3 showed 1 or 2 amino acid (aa) insertions at position 35 of the HIV-1 protease gene. Protease genes containing aa insertions, either in the presence (ins35G+res.muts, ins35TN+res.muts) or absence (ins35G, ins35TN) of other resistance mutations, were introduced into the wild-type HIV-1 strain NL4-3. The introduction of ins35G and ins35TN in the wild-type protease confirmed that these mutations were per se not responsible of decreased drug susceptibility. The replication rate of mutant recombinant viruses was determined by HIV RNA quantification in supernatants of cell cultures in comparison with a recombinant HIV-1 strain with wild-type protease. Recombinant ins35G and ins35TN HIV-1 strains did not display increased resistance to currently used protease inhibitors (PIs). Comparison of ins35TN+res.muts and ins35G+res.muts with respect to the corresponding recombinant rescue mutants showed that ins35TN decreased the replication rate of the PI-resistant strain, while ins35G had a protective effect.

Original languageEnglish
Pages (from-to)181-185
Number of pages5
JournalAntiviral Research
Volume69
Issue number3
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Virus Replication
Antiviral Agents
HIV-1
Peptide Hydrolases
Protease Inhibitors
Amino Acids
Mutation
Highly Active Antiretroviral Therapy
Genes
Cell Culture Techniques
HIV
RNA
Viruses
Pharmaceutical Preparations
Human immunodeficiency virus 1 p16 protease

Keywords

  • Drug resistance
  • HIV-1
  • Insertion
  • Protease
  • Viral replication

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

@article{c10f79f326de451ab17c5189ad5928d1,
title = "Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility",
abstract = "Among 1330 patients undergoing highly active antiretroviral therapy (HAART), 3 showed 1 or 2 amino acid (aa) insertions at position 35 of the HIV-1 protease gene. Protease genes containing aa insertions, either in the presence (ins35G+res.muts, ins35TN+res.muts) or absence (ins35G, ins35TN) of other resistance mutations, were introduced into the wild-type HIV-1 strain NL4-3. The introduction of ins35G and ins35TN in the wild-type protease confirmed that these mutations were per se not responsible of decreased drug susceptibility. The replication rate of mutant recombinant viruses was determined by HIV RNA quantification in supernatants of cell cultures in comparison with a recombinant HIV-1 strain with wild-type protease. Recombinant ins35G and ins35TN HIV-1 strains did not display increased resistance to currently used protease inhibitors (PIs). Comparison of ins35TN+res.muts and ins35G+res.muts with respect to the corresponding recombinant rescue mutants showed that ins35TN decreased the replication rate of the PI-resistant strain, while ins35G had a protective effect.",
keywords = "Drug resistance, HIV-1, Insertion, Protease, Viral replication",
author = "Stefania Paolucci and Fausto Baldanti and Luca Dossena and Giuseppe Gerna",
year = "2006",
month = "3",
doi = "10.1016/j.antiviral.2005.12.005",
language = "English",
volume = "69",
pages = "181--185",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility

AU - Paolucci, Stefania

AU - Baldanti, Fausto

AU - Dossena, Luca

AU - Gerna, Giuseppe

PY - 2006/3

Y1 - 2006/3

N2 - Among 1330 patients undergoing highly active antiretroviral therapy (HAART), 3 showed 1 or 2 amino acid (aa) insertions at position 35 of the HIV-1 protease gene. Protease genes containing aa insertions, either in the presence (ins35G+res.muts, ins35TN+res.muts) or absence (ins35G, ins35TN) of other resistance mutations, were introduced into the wild-type HIV-1 strain NL4-3. The introduction of ins35G and ins35TN in the wild-type protease confirmed that these mutations were per se not responsible of decreased drug susceptibility. The replication rate of mutant recombinant viruses was determined by HIV RNA quantification in supernatants of cell cultures in comparison with a recombinant HIV-1 strain with wild-type protease. Recombinant ins35G and ins35TN HIV-1 strains did not display increased resistance to currently used protease inhibitors (PIs). Comparison of ins35TN+res.muts and ins35G+res.muts with respect to the corresponding recombinant rescue mutants showed that ins35TN decreased the replication rate of the PI-resistant strain, while ins35G had a protective effect.

AB - Among 1330 patients undergoing highly active antiretroviral therapy (HAART), 3 showed 1 or 2 amino acid (aa) insertions at position 35 of the HIV-1 protease gene. Protease genes containing aa insertions, either in the presence (ins35G+res.muts, ins35TN+res.muts) or absence (ins35G, ins35TN) of other resistance mutations, were introduced into the wild-type HIV-1 strain NL4-3. The introduction of ins35G and ins35TN in the wild-type protease confirmed that these mutations were per se not responsible of decreased drug susceptibility. The replication rate of mutant recombinant viruses was determined by HIV RNA quantification in supernatants of cell cultures in comparison with a recombinant HIV-1 strain with wild-type protease. Recombinant ins35G and ins35TN HIV-1 strains did not display increased resistance to currently used protease inhibitors (PIs). Comparison of ins35TN+res.muts and ins35G+res.muts with respect to the corresponding recombinant rescue mutants showed that ins35TN decreased the replication rate of the PI-resistant strain, while ins35G had a protective effect.

KW - Drug resistance

KW - HIV-1

KW - Insertion

KW - Protease

KW - Viral replication

UR - http://www.scopus.com/inward/record.url?scp=32644466593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32644466593&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2005.12.005

DO - 10.1016/j.antiviral.2005.12.005

M3 - Article

C2 - 16460817

AN - SCOPUS:32644466593

VL - 69

SP - 181

EP - 185

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 3

ER -